Clarivate Introduces IPOne
Get Alerts CLVT Hot Sheet
Join SI Premium – FREE
A unified IP intelligence platform for AI-powered research ecosystem, workflow automation and enterprise AI connectors
Through the new unified IP intelligence platform, law firms and corporate IP teams will leverage Clarivate AI agents to seamlessly connect trusted proprietary IP data, including Derwent patent, Darts-ip litigation and CompuMark trademark and industrial design data, to support IP workflows and decision-making. The IPOne solution is being specifically developed for high-value use cases such as discovery, clearance, prioritization, monitoring, analysis and decision support across the IP lifecycle.
The IPOne platform includes Model Context Protocols (MCPs) to enable secure integration with enterprise AI tools. MCPs, an open standard that allows AI tools to securely connect to external data sources, tools and services, integrate authoritative intelligence into enterprise LLM platforms. As a result, organizations can embed trusted IP intelligence directly into their systems to enhance decision-making while preserving transparency and control.
Sign up to stay informed and receive updates about IPOne.
About Clarivate
Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com
Media contact:
Sofia Nogues, Sr. External Communications Manager
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/clarivate-introduces-ipone-302784619.html
SOURCE Clarivate Plc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- LG Display OLED becomes world's first to achieve "Perfect Color/Brightness" certification
- Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
- LOTTE Biologics Completes Construction of Songdo Bio Campus Plant 1 and Obtains Approval for Use
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share